Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Blood

Volumn 122, Issue 10, 2013, Pages 1761-1769

  Opatz, Sabrina ^a,b   Polzer, Harald ^a,c   Herold, Tobias ^a,c   Konstandin, Nikola P ^a   Ksienzyk, Bianka ^a   Zellmeier, Evelyn ^a   Vosberg, Sebastian ^a,c   Graf, Alexander ^d   Krebs, Stefan ^d   Blum, Helmut ^d   Hopfner, Karl Peter ^e   Kakadia, Purvi M ^a,f   Schneider, Stephanie ^a   Dufour, Annika ^a   Braess, Jan ^g   Sauerland, Maria Cristina ^h   Berdel, Wolfgang E ^h   Büchner, Thomas ^h   Woermann, Bernhard J ⁱ   Hiddemann, Wolfgang ^a,b,c   Spiekermann, Karsten ^a,b,c   Bohlander, Stefan K ^c,f   Greif, Philipp A ^a,b,c   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Laboratory for Functional Genome Analysis ^*  (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g Oncology and Hematology   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ German Society of Hematology and Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CBFB MYH11 FUSION PROTEIN; CD135 ANTIGEN; HYBRID PROTEIN; RUNX1 RUNX1T1 FUSION PROTEIN; UNCLASSIFIED DRUG; BENZOTHIAZOLE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CBFB PROTEIN, HUMAN; CBFBETA MYH11 FUSION PROTEIN; CBFBETA-MYH11 FUSION PROTEIN; CORE BINDING FACTOR BETA; CYTOKINE; DRUG DERIVATIVE; FLT3 PROTEIN, HUMAN; MIDOSTAURIN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; QUIZARTINIB; STAUROSPORINE;

ADULT; AGED; ARTICLE; BINDING SITE; CONTROLLED STUDY; DE NOVO ACUTE MYELOID LEUKEMIA; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; WHOLE EXOME SEQUENCING; ADOLESCENT; AMINO ACID SUBSTITUTION; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; EXOME; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA; MIDDLE AGED; MOLECULAR GENETICS; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; APOPTOSIS; BASE SEQUENCE; BENZOTHIAZOLES; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR BETA SUBUNIT; CYTOKINES; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, FUSION; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; STAUROSPORINE;

EID: 84886515357     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-476473     Document Type: Article

References (32)

1. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2(7):502-513.
2. Mrózek K, Bloomfield CD. Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia. J Natl Cancer Inst Monogr. 2008;(39):52-57.
3. Castilla LH, Perrat P, Martinez NJ, et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci USA. 2004;101(14): 4924-4929.
4. Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest. 2005;115(8):2159-2168.
5. Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012;12(1):304.
6. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002;39(4 Suppl 3):6-11.
7. Boissel N, Leroy H, Brethon B, et al; Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-970.
8. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood. 2006; 107(10):3847-3853.
9. Paschka P, Marcucci G, Ruppert AS, et al; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911.
10. Valk PJ, Bowen DT, Frew ME, Goodeve AC, Löwenberg B, Reilly JT. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). Haematologica. 2004; 89(1):106.
11. Haferlach C, Dicker F, Kohlmann A, et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia. 2010;24(5):1065-1069.
12. Cools J, Mentens N, Furet P, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004;64(18): 6385-6389.
13. Pauwels D, Sweron B, Cools J. The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220. Haematologica. 2012;97(11):1773-1774.
14. Heidel F, Solem FK, Breitenbuecher F, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006; 107(1):293-300.
15. Greif PA, Dufour A, Konstandin NP, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood. 2012;120(2): 395-403.
16. Reindl C, Bagrintseva K, Vempati S, et al. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood. 2006;107(9):3700-3707.
17. Polzer H, Janke H, Schmid D, Hiddemann W, Spiekermann K. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases. Exp Hematol. 2012;41(3):271-280.
18. Reindl C, Quentmeier H, Petropoulos K, et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res. 2009;15(7): 2238-2247.
19. Herold T, Jurinovic V, Metzeler KH, et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia. 2011;25(10): 1639-1645.
20. Li Z, Herold T, He C, et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol. 2013;31(9):1172-1181.
21. Ferrari F, Bortoluzzi S, Coppe A, et al. Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformatics. 2007;8:446.
22. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
23. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
24. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
25. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113-2119.
26. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326-4335.
27. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59-66.
28. Schmidt-Arras DE, Böhmer A, Markova B, Choudhary C, Serve H, Böhmer FD. Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol. 2005;25(9): 3690-3703.
29. Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13(2): 169-178.
30. Walter M, Lucet IS, Patel O, et al. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol. 2007;367(3): 839-847.
31. Fröhling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6): 501-513.
32. Hu S, Niu H, Minkin P, et al. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther. 2008;7(5):1110-1120.